Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3567635

NC(=O)c1ccnc2ccncc12.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.54
KDM4E B2RXH2 5/20 0.45
TDP1 Q9NUW8 2/20 0.41
SIRT3 Q9NTG7 1/20 0.41
SLC22A12 Q96S37 3/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
KDM6B O15054 1/20 0.38
KDM4A O75164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
ASPH Q12797 1/20 0.34
KDM8 Q8N371 1/20 0.34
LMNA P02545 1/20 0.34
PIM1 P11309 2/20 0.34
MKNK2 Q9HBH9 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577315 0.89 KDM4E (0.53) L3MBTL1KDM4ETDP1SIRT3SLC22A12
Trifluoroacetic Acid SCHEMBL28146694 0.82 L3MBTL1 (0.64) L3MBTL1KDM4ESLC22A12KMT2ASLC40A1
Trifluoroacetic Acid SCHEMBL3567636 0.82 NCF1 (0.42) L3MBTL1KDM4ETDP1SLC22A12HTT
SCHEMBL8413518 0.78 KDM4C (0.52) L3MBTL1KDM4ETDP1SLC22A12KMT2A
SCHEMBL5799150 0.77 KDM4E (0.49) L3MBTL1KDM4ETDP1SIRT3HTT
Trifluoroacetic Acid SCHEMBL29418884 0.75 EGFR (0.43) SLC22A12MAP4K4CDK5
Trifluoroacetic Acid SCHEMBL31662344 0.75 EGFR (0.43) SLC22A12MAP4K4CDK5
Trifluoroacetic Acid SCHEMBL2157990 0.70 L3MBTL1 (0.51) L3MBTL1SLC22A12HTTKMT2AMEN1
SCHEMBL607663 0.70 KDM4E (0.57) L3MBTL1KDM4EHTTKMT2AMAPT
SCHEMBL29381262 0.70 KDM4E (0.57) L3MBTL1KDM4EHTTKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US disclosed
US-7622481-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP disclosed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US disclosed
EP-1537123-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-06-08 EP disclosed
WO-2004002992-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189604-A1 Compounds ELANE, PIGS, SDHA L3MBTL1 797/4885KDM4E 3723/4885TDP1 3265/4885
US-20100081650-A1 Antimicrobial Compounds ELANE, NISCH, PIGS L3MBTL1 495/4885KDM4E 4273/4885TDP1 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.